Navigation Links
Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Date:10/26/2007

ntly in a Phase 2 study as a therapy for colorectal cancer, and CPX-351, currently in a Phase 1 study for patients with leukemia, these promising results, indicating broad potential anti-tumor activity for CPX-571, represent another validation of Celator's CombiPlex technology platform," said Andrew Janoff, Ph.D., CEO of Celator.

CombiPlex(TM), Celator's proprietary technology platform, identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered to patients.

"Based on these findings, there is significant support to advance CPX-571 to clinical development in the treatment of small cell lung cancers and potentially for use in treating other types of cancer," said Arthur Louie, M.D., Celator's chief medical officer.

ABOUT CELATOR

Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX 571, now positioned to advance to Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
5. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
6. RT-PCR Primers for the Study of Apoptosis
7. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
10. Medical College receives $377K to study brain disease
11. Kauffman study shows consistent entrepreneurial growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... Loestrin 24 Fe and Taclonex, ST. DAVID,S, Bermuda, ... today announced its results for the quarter and year,ended ... 31, 2007,totaled $227.7 million, an increase of 10.3%, over ... 31, 2007 totaled $899.6 million, an,increase of 19.2% over ...
... 29 Wyeth Pharmaceuticals,a division of Wyeth (NYSE: ... its,collaboration agreements with Solvay Pharmaceuticals for the development,and ... in earlier,stages of development for the potential treatment ... the collaboration with Solvay after assessing the,opportunity for ...
... SAN FRANCISCO, Calif., Feb. 28 ,Exelixis, Inc. (Nasdaq: ... director of investor relations, will present at the,Susquehanna SIGnificant ... a.m. PT on Tuesday, March 4, 2008., The ... the Event,Calendar page under Investors on the Exelixis website ...
Cached Biology Technology:Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 17Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds 2
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... today announced BD & Guidepoint Mentor, ... free access to Guidepoint,s expert network services. ... developing cutting-edge technologies to improve healthcare delivery and outcomes ... manager, each start-up entrepreneur will be able to directly ...
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Broadlawns Medical Center is reading palms in order to ... plan and commitment to be the Iowa leader in Electronic ... scanners to register and check-in patients. The new system, called ... Broadlawns Medical Center as part of a week-long launch.   ...
... children were born in public clinics in Denmark, projecting a net ... 50 years respectively. The authors of the study calculated that reductions ... to cost savings of 67 - 111 million for the Danish ... 50 years of age, the government would have lost 74 - ...
... Results from a study of over 50 000 pregnancies ... pregnancy was confirmed gave birth to babies with a ... never smoked, Professor Nick Macklon, from the Department of ... annual conference of the European Society of Human Reproduction ...
Cached Biology News:Broadlawns Installs First-in-Iowa Biometric Patient Identity Security System 2Broadlawns Installs First-in-Iowa Biometric Patient Identity Security System 3The long-term fiscal impact of funding cuts for IVF in Denmark 2Giving up smoking averts the adverse birth outcomes associated with tobacco 2
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
Biology Products: